Neuroprotection Therapeutics Market
Neuroprotection Therapeutics Market Analysis By Product (Free Radical Trapping Agents, Glutamate Antagonists, Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors & Other Products) By Medical Condition, Application, End-User & Region – Global Insights 2022 to 2027
Analysis of Neuroprotection Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Neuroprotection Therapeutics Market Outlook (2022-2027)
The global neuroprotection therapeutics market is anticipated to expand rapidly at a CAGR of 6.8% over the 2022-2027 forecast period. The market is expected to secure a market value of around US$ 85.1 billion by 2027, up from US$ 61.25 billion in 2022.
Neuroprotection therapeutics shield the brain's neurons against damage and deterioration. These drugs are used to treat a variety of disorders of the central nervous system, including traumatic brain injuries, Parkinson's disease, and Alzheimer's disease.
Age considerably raises the prevalence of neurological diseases. Thus, when average life expectancy rises, there will be greater demand for neuroprotective therapies, creating a sizable market for new medications to treat these illnesses.
Report Attributes |
Details |
|---|---|
|
Neuroprotection Therapeutics Market Size (2022) |
US$ 61.25 Billion |
|
Projected Market Value (2027) |
US$ 85.1 Billion |
|
Global Market Growth Rate (2022-2027) |
6.8% CAGR |
|
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Demand Analysis of Neuroprotection Therapeutics (2017-2021) Vs. Market Outlook (2022-2027)
“Increasing Stroke & Traumatic Central Nervous System Injuries Driving Demand for Neuroprotection Therapeutics”
According to Fact.MR- a market research and competitive intelligence provider- worldwide demand for neuroprotection therapeutics and drugs is expected to increase at a CAGR of 6.8% from 2022 to 2027.
The need for the treatment of brain injuries primarily brought on by auto accidents and the rising incidence of neurodegenerative illnesses, particularly in older populations are factors driving the demand for neuroprotective therapies.
The potential for the introduction of innovative medications is significantly increased by the high incidence of neurogenerative disease and the dearth of particular therapeutic alternatives.
Some of the key drivers anticipated to propel market expansion during the forecast period include increasing stroke and traumatic central nervous system injuries. One of the key drivers propelling market expansion is the increased demand for the product for a variety of uses in hospitals, medical facilities, and nursing homes.
Therapeutics for neuroprotection may lessen the effects of stroke. Small-molecule medicines, therapeutic monoclonal antibodies, gene and cell treatments, and other substances are among the medications for neuroprotection that are now under clinical development. A process called neuroprotection, or the prevention of neuronal loss, is mediated by numerous biological mechanisms.
Trauma, shock, stroke, sepsis, traumatic brain injury (TBI), and burst brain aneurysms are the most prevalent disorders linked to nervous system involvement, and their rising incidence is the main factor driving the neuro critical care market expansion.
Why is Demand for Neuroprotection Therapeutics Rising Rapidly?
“Implementation of Medical Professional Training Programs in Healthcare Facilities to Surge Adoption of Neuroprotection Therapeutics”
The market for neuroprotection therapeutics may see many potential opportunities due to technological developments in the healthcare industry and the rising demand for innovative neuroprotective products in light of considerable research on drugs for the effective preservation of brain cells.
Therapeutics for neuroprotection offer drugs that shield the brain and central nervous system. These products work well to regenerate cells that may have been damaged by trauma or stress. These features and advantages could significantly boost the market for neuroprotection therapeutics.
The market for neuroprotection treatments is expected to rise due to the steadily growing senior population and the increased occurrence of disorders affecting the central nervous system.
The market for neuroprotection medicines will have a lot of room to develop as a result of the healthcare industry's growing demand for these drugs. The prevalence of life-threatening illnesses and brain injuries is projected to rise, creating new opportunities for the market for neuroprotection therapeutics to expand.
The development of diagnostic and therapeutic approaches, which has produced remarkable outcomes, has been greatly aided by the next-generation products. These advancements could portend the market for neuroprotection therapeutics expanding over the coming years.
The implementation of medical professional training programs in healthcare facilities to ensure that patients receive the best care possible could act as a growth factor for the neuroprotective agents market.
With government financing and initiatives, the emphasis on creating a complete and well-equipped hospital infrastructure has grown significantly over time. Government organizations are adopting a variety of actions to upgrade healthcare infrastructure and offer kind reimbursement practices.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What is Impeding Neuroprotection Therapeutics Market Revenue Growth?
“Strict Regulatory Approvals & High Costs Associated with Related R&D”
The lack of clinical research, high costs associated with R&D, strict regulatory approvals, and the high failure rate of a majority of potential medications in clinical trials restrain market expansion to some extent.
Why is North America Expected to Lead the Neuroprotection Therapeutics Market?
“High Popularity of Preventative Healthcare Practices in North America”
North America is anticipated to occupy a significant market share in the neuroprotection therapeutics market during the projection period. The Parkinson's Foundation estimates that 60,000 Americans receive a Parkinson's diagnosis each year. Consequently, North America is the main market for neuroprotection therapeutics.
Nearly 5 to 7 million people worldwide are thought to have Parkinson's disease, which would raise the need for neuroprotective medications and encourage research and development. This is addressed by the rising popularity of preventative healthcare practices in North America.
Country-wise Insights
What are the Growth Prospects for the U.S. Neuroprotection Therapeutics Market?
“Increasing Government Support & Funding for Research Initiatives in the U.S.”
The U.S. neuroprotection therapeutics market is projected to expand at the highest CAGR from 2022 to 2027. The number of geriatricians in the United States will need to nearly triple by 2050 to appropriately care for the anticipated number of people with Alzheimer's disease, according to the Alzheimer's Association. As a result, an expanding patient base is anticipated to aid in the market expansion over the coming years.
Due to the growing impact of the disease, government support and funding for research initiatives are rising. The U.S. Congress contributed roughly US$ 10 million to multiple sclerosis research and may provide an additional US$ 20 million. The U.S. market is expanding as a result of expanding healthcare infrastructure, supportive government programs, and increased illness burden.
Why is China a Prominent Neuroprotection Therapeutics Market?
“Rapid Expansion of Biopharmaceutical Industry in China”
The neuroprotection therapeutics market in China is anticipated to rise at a CAGR of 6.5% from 2022 to 2027. The demand for neuroprotective drugs in the region is anticipated to rise due to the established biopharmaceutical industry, large population, growing research activities, and growing demand for highly effective medications for rare neurological disease treatment.
Market expansion in China is being driven by the use of neuroprotective products along with recent technological advancements, higher spending on healthcare modernization programs, and the rise of medical tourism.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Category-wise Insights
Which Neuroprotection Therapeutic Product is Expected to Be Hugely Popular Over the Coming Years?
“Improved Effectiveness of Free Radical Trapping Agents in Halting Deterioration of Neural Cells”
Based on product, the neuroprotection therapeutics market is segmented into glutamate antagonists (anti-excitotoxic agents), free radical trapping agents (antioxidants), anti-inflammatory agents, neurotrophic factors (NTFs), and apoptosis inhibitors.
Free radical trapping agents (antioxidants) account for 38% share of the global neuroprotection therapeutics market. The significant rise is a result of the increased use of free radical trapping agents in the treatment of neurological diseases such as Alzheimer's and the improved effectiveness of antioxidants in halting the further deterioration of neural cells.
The rising need for effective medications, rising use of herbal extracts that trap free radicals, and increasing R&D efforts are the factors driving the demand for free radical trapping agents (antioxidants).
Which Medical Condition Accounts for Highest Need for Neuroprotection Therapeutics?
“Rise in R&D Efforts for Creation of Novel Drugs in Alzheimer's Disease Treatment”
Demand for neuroprotection therapeutics in Alzheimer's disease treatment remains dominant over other medical conditions such as dementia, epilepsy, and multiple sclerosis.
Alzheimer's symptoms include anxiety, loss of memory, lack of inhibitions, and problems with logic and understanding. It is frequently diagnosed through physical examinations, laboratory tests, brain imaging, mental status exams, and neuropsychological evaluation. As the world's population ages, the incidence of Alzheimer's disease rises, creating prospects for market expansion in the Alzheimer's treatment sector.
According to the World Population Prospects (WPP) report from the UN, there will be 1.4 billion Alzheimer's disease patients worldwide by 2030, growing at a pace of 3% each year. However, treatments for Alzheimer's are being developed and are expected to go on sale soon, spurring market expansion.
A rise in the demand for therapeutic targets, a rise in research & development efforts for the creation of novel drugs and therapies, an increase in the prevalence of Alzheimer's disease in the population, and an increase in spending on the healthcare infrastructure are all factors that have contributed to the growth of the Alzheimer's disease treatment industry.
Cotinine has been developed as a neuroprotective agent, and it enhances the performance of tasks involving the processing of information, concentration, and memory that are relevant to Alzheimer's disease.
Competitive Landscape
Companies in the neuroprotective therapeutics market are putting increased emphasis on spending money on product innovation and launches, along with enhancements to usefulness and result accuracy.
For instance :
- In 2021, Merck KGaA invested in Synthekine, a cytokine bioresearch firm, to increase the company's capabilities in the management of autoimmune illnesses.
Key Segments in Neuroprotection Therapeutics Industry Research
-
By Product :
- Free Radical Trapping Agents (Antioxidants)
- Glutamate Antagonists (Anti-Excitotoxic Agents)
- Apoptosis Inhibitors
- Anti-inflammatory Agents
- Neurotrophic Factors (NTFs)
- Other Products
-
By Medical Condition :
- Alzheimer's Disease
- Dementia
- Epilepsy
- Multiple Sclerosis
-
By Application :
- Prevention
- Treatment
-
By End User :
- Hospitals
- Clinics
- Others
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Key Findings 1.1.1. Overall Neuroprotection Therapeutics Market 1.1.2. Segment Overview 1.1.3. Regional Overview 1.1.4. Competitor’s Focus 1.1.5. Consumer’s Perception 1.2. Summary of Statistics 1.3. Market Characteristics and Attributes 2. Market Overview 2.1. Introduction and Definition 2.2. Research Scope 3. COVID 19 Impact Assessment 3.1. Demand in Neuroprotection Therapeutics Market 3.1.1. Global Neuroprotection Therapeutics Market Quarterly Market Value Analysis (US$ Mn), 2022 3.1.2. Global Neuroprotection Therapeutics Market Value Y-o-Y Growth Pre and Post Crisis Projection 3.1.3. Global Neuroprotection Therapeutics Market Recalibrated Growth Projection (US$ Mn) 3.2. Neuroprotection Therapeutics Market Shrink and Recovery Trend Assessment, by Region 3.3. Neuroprotection Therapeutics Market Recalibrated Market and Growth Assessment, by Region 4. Market Background 4.1. Country wise Market Attractiveness Index 4.2. Neuroprotection Therapeutics Market Scenario-based Forecast 4.3. Value Chain Analysis 4.3.1. List of Manufacturers 4.3.2. List of Online Retailers 4.3.3. List of End Users 4.4. Investment Feasibility Assessment 4.4.1. Investment Feasibility for Neuroprotection Therapeutics Market 4.5. Porter’s Five Forces Analysis 4.5.1. Bargaining Power of Buyers 4.5.2. Bargaining Power of Suppliers 4.5.3. Threat of Substitute Product Types 4.5.4. Threat of New Entrants 4.5.5. Intensity of Rivalry 4.5.6. 5 Forces Acting Upon Neuroprotection Therapeutics Market 4.6. PESTEL Analysis 4.7. Forecast Factors 4.7.1. Increasing Government Regulations 4.7.2. Expansion of Industry 4.7.3. Compliance to Insurance Regulations 4.7.4. Advancements in Market 4.7.5. Increasing Global Temperature 4.7.6. Technological Advancements 4.8. Market Dynamics 4.8.1. Market Drivers 4.8.2. Market Restraints 4.8.3. Opportunity Windows 4.8.4. Key Trends 5. Global Neuroprotection Therapeutics Market Pricing Analysis 5.1. Price Point Assessment 5.1.1. Weighted Average Pricing (2021), by Region 5.1.2. Key Factors Influencing Pricing 5.1.3. Price Benchmark by Region 5.1.4. Price Benchmark by Medical Condition 6. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027) 6.1. Market Overview 6.2. Introduction to Market Statistics 6.2.1. Global Neuroprotection Therapeutics Market Volume (Units) 6.2.2. Global Neuroprotection Therapeutics Market Value (US$ Mn) 6.2.3. Global Neuroprotection Therapeutics Cumulative Historical Market and Absolute $ Opportunity 6.3. Y-o-Y Growth and Incremental Opportunity 6.4. Absolute Dollar Historical Market and Absolute Dollar Opportunity 7. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027), by Medical Condition 7.1. Introduction 7.1.1. Neuroprotection Therapeutics Medical Condition Definition 7.1.1.1. Alzheimer's Disease 7.1.1.2. Dementia 7.1.1.3. Epilepsy 7.1.1.4. Multiple Sclerosis 7.1.2. Neuroprotection Therapeutics Market Key Findings, by Medical Condition 7.1.2.1. Absolute $ Opportunity (2022–2027) 7.1.2.2. Market Share and BPS Analysis 7.1.2.3. Y-o-Y Growth Projections 7.1.2.4. Market Attractiveness Analysis 7.2. Global Neuroprotection Therapeutics Market Regional Market Share Comparison, by Medical Condition 8. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027), by Product 8.1. Introduction 8.1.1. Neuroprotection Therapeutics Product Type Definition 8.1.1.1. Free Radical Trapping Agents (Antioxidants) 8.1.1.2. Glutamate Antagonists (Anti-Excitotoxic Agents) 8.1.1.3. Apoptosis Inhibitors 8.1.1.4. Anti-inflammatory Agents 8.1.1.5. Neurotrophic Factors (NTFs) 8.1.1.6. Other Products 8.1.2. Neuroprotection Therapeutics Market Key Findings, by Product 8.1.2.1. Absolute $ Opportunity (2022–2027) 8.1.2.2. Market Share and BPS Analysis 8.1.2.3. Y-o-Y Growth Projections 8.1.2.4. Market Attractiveness Analysis 8.2. Global Neuroprotection Therapeutics Market Regional Market Share Comparison, by Product 9. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027), by Application 9.1. Introduction 9.1.1. Neuroprotection Therapeutics Application Definition 9.1.1.1. Prevention 9.1.1.2. Treatment 9.1.2. Neuroprotection Therapeutics Market Key Findings, by Application 9.1.2.1. Absolute $ Opportunity (2022–2027) 9.1.2.2. Market Share and BPS Analysis 9.1.2.3. Y-o-Y Growth Projections 9.1.2.4. Market Attractiveness Analysis 9.2. Global Neuroprotection Therapeutics Market Regional Market Share Comparison, by Application 10. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027), by End User 10.1. Introduction 10.1.1. Neuroprotection Therapeutics End User Definition 10.1.1.1. Hospitals 10.1.1.2. Clinics 10.1.1.3. Others 10.1.2. Neuroprotection Therapeutics Market Key Findings, by End User 10.1.2.1. Absolute $ Opportunity (2022–2027) 10.1.2.2. Market Share and BPS Analysis 10.1.2.3. Y-o-Y Growth Projections 10.1.2.4. Market Attractiveness Analysis 10.2. Global Neuroprotection Therapeutics Market Regional Market Share Comparison, by End User 11. Global Neuroprotection Therapeutics Market Analysis (2017-2021) and Forecast (2022–2027), by Region 11.1. Introduction 11.1.1. Neuroprotection Therapeutics Regional Coverage 11.1.1.1. North America 11.1.1.2. Europe 11.1.1.3. East Asia 11.1.1.4. South Asia 11.1.1.5. Latin America 11.1.1.6. Middle East & Africa (MEA) 11.1.1.7. Oceania 11.1.2. Neuroprotection Therapeutics Market Key Findings, by Region 11.1.2.1. Absolute $ Opportunity (2022–2027) 11.1.2.2. Market Share and BPS Analysis 11.1.2.3. Y-o-Y Growth Projections 11.1.2.4. Market Attractiveness Analysis 11.2. Global Neuroprotection Therapeutics Market Regional Market Share Comparison, by Region 12. North America Neuroprotection Therapeutics Market Analysis and Forecast 12.1. Overview 12.1.1. North America Share in Global Neuroprotection Therapeutics Market 12.2. Market Value & Volume Forecast and Analysis 12.2.1. By Country 12.2.1.1. U.S. 12.2.1.2. Canada 12.2.2. By Medical Condition 12.2.3. By Product 12.2.4. By Application 12.2.5. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Medical Condition 12.3.3. By Product 12.3.4. By Application 12.3.5. By End User 12.4. Y-o-Y Growth Comparison 13. Europe Neuroprotection Therapeutics Market Analysis and Forecast 13.1. Overview 13.1.1. Europe Share in Global Neuroprotection Therapeutics Market 13.2. Market Value & Volume Forecast and Analysis 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Russia 13.2.1.5. Spain 13.2.1.6. Italy 13.2.1.7. Rest of Europe 13.2.2. By Medical Condition 13.2.3. By Product 13.2.4. By Application 13.2.5. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. United Kingdom 13.3.1.3. France 13.3.1.4. Russia 13.3.1.5. Spain 13.3.1.6. Italy 13.3.1.7. Rest of Europe 13.3.2. By Medical Condition 13.3.3. By Product 13.3.4. By Application 13.3.5. By End User 13.4. Y-o-Y Growth Comparison 14. East Asia Neuroprotection Therapeutics Market Analysis and Forecast 14.1. Overview 14.1.1. East Asia Share in Global Neuroprotection Therapeutics Market 14.2. Market Value & Volume Forecast and Analysis 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Medical Condition 14.2.3. By Product 14.2.4. By Application 14.2.5. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Medical Condition 14.3.3. By Product 14.3.4. By Application 14.3.5. By End User 14.4. Y-o-Y Growth Comparison 15. South Asia Neuroprotection Therapeutics Market Analysis and Forecast 15.1. Overview 15.1.1. South Asia Share in Global Neuroprotection Therapeutics Market 15.2. Market Value & Volume Forecast and Analysis 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Singapore 15.2.1.3. Indonesia 15.2.1.4. Thailand 15.2.1.5. Rest of South Asia 15.2.2. By Medical Condition 15.2.3. By Product 15.2.4. By Application 15.2.5. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Singapore 15.3.1.3. Indonesia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Medical Condition 15.3.3. By Product 15.3.4. By Application 15.3.5. By End User 15.4. Y-o-Y Growth Comparison 16. Latin America Neuroprotection Therapeutics Market Analysis and Forecast 16.1. Overview 16.1.1. Latin America Share in Global Neuroprotection Therapeutics Market 16.2. Market Value & Volume Forecast and Analysis 16.2.1. By Country 16.2.1.1. Brazil 16.2.1.2. Mexico 16.2.1.3. Rest of LATAM 16.2.2. By Medical Condition 16.2.3. By Product 16.2.4. By Application 16.2.5. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Rest of LATAM 16.3.2. By Medical Condition 16.3.3. By Product 16.3.4. By Application 16.3.5. By End User 16.4. Y-o-Y Growth Comparison 17. Middle East & Africa Neuroprotection Therapeutics Market Analysis and Forecast 17.1. Overview 17.1.1. Middle East & Africa Share in Global Neuroprotection Therapeutics Market 17.2. Market Value & Volume Forecast and Analysis 17.2.1. By Country 17.2.1.1. Turkey 17.2.1.2. GCC Countries 17.2.1.3. South Asia 17.2.1.4. Rest of MEA 17.2.2. By Medical Condition 17.2.3. By Product 17.2.4. By Application 17.2.5. By End User 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.1.1. Turkey 17.3.1.2. GCC Countries 17.3.1.3. South Asia 17.3.1.4. Rest of MEA 17.3.2. By Medical Condition 17.3.3. By Product 17.3.4. By Application 17.3.5. By End User 17.4. Y-o-Y Growth Comparison 18. Oceania Neuroprotection Therapeutics Market Analysis and Forecast 18.1. Overview 18.1.1. Oceania Share in Global Neuroprotection Therapeutics Market 18.2. Market Value & Volume Forecast and Analysis 18.2.1. By Country 18.2.1.1. Australia 18.2.1.2. New Zealand 18.2.2. By Medical Condition 18.2.3. By Product 18.2.4. By Application 18.2.5. By End User 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Medical Condition 18.3.3. By Product 18.3.4. By Application 18.3.5. By End User 18.4. Y-o-Y Growth Comparison 19. Global Neuroprotection Therapeutics Market Analysis Key Countries 19.1. US 19.1.1. Share of North American Market 19.1.2. Market Share, by Medical Condition, 2022 19.1.3. Market Share, by Product, 2022 19.1.4. Market Value (US$ Mn) and Forecast 2022–2027 19.1.5. Market Share, by End User, 2022 19.2. Canada 19.2.1. Share of North American Market 19.2.2. Market Share, by Medical Condition, 2022 19.2.3. Market Share, by Product, 2022 19.2.4. Market Value (US$ Mn) and Forecast 2022–2027 19.2.5. Market Share, by End User, 2022 19.3. Germany 19.3.1. Share of European Market 19.3.2. Market Share, by Medical Condition, 2022 19.3.3. Market Share, by Product, 2022 19.3.4. Market Value (US$ Mn) and Forecast 2022–2027 19.3.5. Market Share, by End User, 2022 19.4. United Kingdom 19.4.1. Share of European Market 19.4.2. Market Share, by Medical Condition, 2022 19.4.3. Market Share, by Product, 2022 19.4.4. Market Value (US$ Mn) and Forecast 2022–2027 19.4.5. Market Share, by End User, 2022 19.5. France 19.5.1. Share of European Market 19.5.2. Market Share, by Medical Condition, 2022 19.5.3. Market Share, by Product, 2022 19.5.4. Market Value (US$ Mn) and Forecast 2022–2027 19.5.5. Market Share, by End User, 2022 19.6. Russia 19.6.1. Share of European Market 19.6.2. Market Share, by Medical Condition, 2022 19.6.3. Market Share, by Product, 2022 19.6.4. Market Value (US$ Mn) and Forecast 2022–2027 19.6.5. Market Share, by End User, 2022 19.7. Spain 19.7.1. Share of European Market 19.7.2. Market Share, by Medical Condition, 2022 19.7.3. Market Share, by Product, 2022 19.7.4. Market Value (US$ Mn) and Forecast 2022–2027 19.7.5. Market Share, by End User, 2022 19.8. Italy 19.8.1. Share of European Market 19.8.2. Market Share, by Medical Condition, 2022 19.8.3. Market Share, by Product, 2022 19.8.4. Market Value (US$ Mn) and Forecast 2022–2027 19.8.5. Market Share, by End User, 2022 19.9. China 19.9.1. Share of East Asian Market 19.9.2. Market Share, by Medical Condition, 2022 19.9.3. Market Share, by Product, 2022 19.9.4. Market Value (US$ Mn) and Forecast 2022–2027 19.9.5. Market Share, by End User, 2022 19.10. Japan 19.10.1. Share of East Asian Market 19.10.2. Market Share, by Medical Condition, 2022 19.10.3. Market Share, by Product, 2022 19.10.4. Market Value (US$ Mn) and Forecast 2022–2027 19.10.5. Market Share, by End User, 2022 19.11. South Korea 19.11.1. Share of East Asian Market 19.11.2. Market Share, by Medical Condition, 2022 19.11.3. Market Share, by Product, 2022 19.11.4. Market Value (US$ Mn) and Forecast 2022–2027 19.11.5. Market Share, by End User, 2022 19.12. India 19.12.1. Share of South Asian Market 19.12.2. Market Share, by Medical Condition, 2022 19.12.3. Market Share, by Product, 2022 19.12.4. Market Value (US$ Mn) and Forecast 2022–2027 19.12.5. Market Share, by End User, 2022 19.13. Singapore 19.13.1. Share of South Asian Market 19.13.2. Market Share, by Medical Condition, 2022 19.13.3. Market Share, by Product, 2022 19.13.4. Market Value (US$ Mn) and Forecast 2022–2027 19.13.5. Market Share, by End User, 2022 19.14. Indonesia 19.14.1. Share of South Asian Market 19.14.2. Market Share, by Medical Condition, 2022 19.14.3. Market Share, by Product, 2022 19.14.4. Market Value (US$ Mn) and Forecast 2022–2027 19.14.5. Market Share, by End User, 2022 19.15. Thailand 19.15.1. Share of South Asian Market 19.15.2. Market Share, by Medical Condition, 2022 19.15.3. Market Share, by Product, 2022 19.15.4. Market Value (US$ Mn) and Forecast 2022–2027 19.15.5. Market Share, by End User, 2022 19.16. Brazil 19.16.1. Share of Latin American Market 19.16.2. Market Share, by Medical Condition, 2022 19.16.3. Market Share, by Product, 2022 19.16.4. Market Value (US$ Mn) and Forecast 2022–2027 19.16.5. Market Share, by End User, 2022 19.17. Mexico 19.17.1. Share of Latin American Market 19.17.2. Market Share, by Medical Condition, 2022 19.17.3. Market Share, by Product, 2022 19.17.4. Market Value (US$ Mn) and Forecast 2022–2027 19.17.5. Market Share, by End User, 2022 19.18. Turkey 19.18.1. Share of MEA Market 19.18.2. Market Share, by Medical Condition, 2022 19.18.3. Market Share, by Product, 2022 19.18.4. Market Value (US$ Mn) and Forecast 2022–2027 19.18.5. Market Share, by End User, 2022 19.19. GCC Countries 19.19.1. Share of MEA Market 19.19.2. Market Share, by Medical Condition, 2022 19.19.3. Market Share, by Product, 2022 19.19.4. Market Value (US$ Mn) and Forecast 2022–2027 19.19.5. Market Share, by End User, 2022 19.20. South Africa 19.20.1. Share of MEA Market 19.20.2. Market Share, by Medical Condition, 2022 19.20.3. Market Share, by Product, 2022 19.20.4. Market Value (US$ Mn) and Forecast 2022–2027 19.20.5. Market Share, by End User, 2022 19.21. Australia 19.21.1. Share of Oceania Market 19.21.2. Market Share, by Medical Condition, 2022 19.21.3. Market Share, by Product, 2022 19.21.4. Market Value (US$ Mn) and Forecast 2022–2027 19.21.5. Market Share, by End User, 2022 19.22. New Zealand 19.22.1. Share of Oceania Market 19.22.2. Market Share, by Medical Condition, 2022 19.22.3. Market Share, by Product, 2022 19.22.4. Market Value (US$ Mn) and Forecast 2022–2027 19.22.5. Market Share, by End User, 2022 20. Competition Landscape 20.1. Global Neuroprotection Therapeutics Market Competition Dashboard 20.2. Global Neuroprotection Therapeutics Market Tier Structure 20.2.1. Market Structure in 2021 20.2.2. Anticipated Market Structure in 2027 20.3. Global Neuroprotection Therapeutics Market Share Analysis 21. Competition Analysis 21.1. Allergan PLC 21.1.1. Company Overview 21.1.2. Product Type Portfolio 21.1.3. Key Strategies 21.1.4. Regional Presence 21.1.5. Key Developments 21.1.6. SWOT Analysis 21.2. Daiichi Sankyo Co., Ltd. 21.2.1. Company Overview 21.2.2. Product Type Portfolio 21.2.3. Key Strategies 21.2.4. Regional Presence 21.2.5. Key Developments 21.2.6. SWOT Analysis 21.3. Astrocyte Pharmaceuticals Inc. 21.3.1. Company Overview 21.3.2. Product Type Portfolio 21.3.3. Key Strategies 21.3.4. Regional Presence 21.3.5. Key Developments 21.3.6. SWOT Analysis 21.4. AstraZeneca PLC 21.4.1. Company Overview 21.4.2. Product Type Portfolio 21.4.3. Key Strategies 21.4.4. Regional Presence 21.4.5. Key Developments 21.4.6. SWOT Analysis 21.5. Biogen, Inc. 21.5.1. Company Overview 21.5.2. Product Type Portfolio 21.5.3. Key Strategies 21.5.4. Regional Presence 21.5.5. Key Developments 21.5.6. SWOT Analysis 21.6. Novartis International AG 21.6.1. Company Overview 21.6.2. Product Type Portfolio 21.6.3. Key Strategies 21.6.4. Regional Presence 21.6.5. Key Developments 21.6.6. SWOT Analysis 21.7. Eli Lilly and Company 21.7.1. Company Overview 21.7.2. Product Type Portfolio 21.7.3. Key Strategies 21.7.4. Regional Presence 21.7.5. Key Developments 21.7.6. SWOT Analysis 21.8. F. Hoffmann-La Roche AG 21.8.1. Company Overview 21.8.2. Product Type Portfolio 21.8.3. Key Strategies 21.8.4. Regional Presence 21.8.5. Key Developments 21.8.6. SWOT Analysis 21.9. Teva Pharmaceutical Industries Ltd. 21.9.1. Company Overview 21.9.2. Product Type Portfolio 21.9.3. Key Strategies 21.9.4. Regional Presence 21.9.5. Key Developments 21.9.6. SWOT Analysis 21.10. Dr. Reddy's Laboratories Ltd. 21.10.1. Company Overview 21.10.2. Product Type Portfolio 21.10.3. Key Strategies 21.10.4. Regional Presence 21.10.5. Key Developments 21.10.6. SWOT Analysis 22. Appendix 23. Definitions of Analytical Frameworks 24. Sources and References
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 02: Global Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 03: Global Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 04: Global Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 05: Global Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 06: Global Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 07: Global Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 08: Global Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 09: Global Neuroprotection Therapeutics Market Volume (Units), by Region, 2017–2027
Table 10: Global Neuroprotection Therapeutics Market Value (US$ Mn), by Region, 2017–2027
Table 11: North America Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 12: North America Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 13: North America Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 14: North America Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 15: North America Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 16: North America Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 17: North America Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 18: North America Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 19: North America Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 20: North America Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 21: Europe Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 22: Europe Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 23: Europe Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 24: Europe Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 25: Europe Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 26: Europe Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 27: Europe Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 28: Europe Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 29: Europe Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 30: Europe Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 31: East Asia Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 32: East Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 33: East Asia Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 34: East Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 35: East Asia Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 36: East Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 37: East Asia Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 38: East Asia Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 39: East Asia Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 40: East Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 41: South Asia Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 42: South Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 43: South Asia Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 44: South Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 45: South Asia Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 46: South Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 47: South Asia Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 48: South Asia Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 49: South Asia Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 50: South Asia Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 51: Latin America Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 52: Latin America Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 53: Latin America Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 54: Latin America Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 55: Latin America Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 56: Latin America Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 57: Latin America Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 58: Latin America Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 59: Latin America Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 60: Latin America Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 61: Middle East and Africa Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 62: Middle East and Africa Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 63: Middle East and Africa Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 64: Middle East and Africa Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 65: Middle East and Africa Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 66: Middle East and Africa Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 67: Middle East and Africa Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 68: Middle East and Africa Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 69: Middle East and Africa Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 70: Middle East and Africa Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
Table 71: Oceania Neuroprotection Therapeutics Market Volume (Units), by Medical Condition, 2017–2027
Table 72: Oceania Neuroprotection Therapeutics Market Value (US$ Mn), by Medical Condition, 2017–2027
Table 73: Oceania Neuroprotection Therapeutics Market Volume (Units), by Product, 2017–2027
Table 74: Oceania Neuroprotection Therapeutics Market Value (US$ Mn), by Product, 2017–2027
Table 75: Oceania Neuroprotection Therapeutics Market Volume (Units), by Application, 2017–2027
Table 76: Oceania Neuroprotection Therapeutics Market Value (US$ Mn), by Application, 2017–2027
Table 77: Oceania Neuroprotection Therapeutics Market Volume (Units), by End User, 2017–2027
Table 78: Oceania Neuroprotection Therapeutics Market Value (US$ Mn), by End User, 2017–2027
Table 79: Oceania Neuroprotection Therapeutics Market Volume (Units), by Country, 2017–2027
Table 80: Oceania Neuroprotection Therapeutics Market Value (US$ Mn), by Country, 2017–2027
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig 01: Global Neuroprotection Therapeutics Market Volume (Units), Value (US$ Thousand) and Y-o-Y Growth, 2017–2027
Fig 02: Global Neuroprotection Therapeutics Absolute $ Historical Market (2017-2021) and Absolute $ Opportunity (2022–2027), US$ Mn
Fig 03: Global Neuroprotection Therapeutics Absolute Historical Volume Market (2017-2021) and Absolute Volume Opportunity (2022–2027), Units
Fig 04: Global Neuroprotection Therapeutics Market Value Y-o-Y Growth and Forecast, 2017–2027
Fig 05: Global Neuroprotection Therapeutics Market Incremental $ Opportunity (US$ Thousand), 2022–2027
Fig 06: Global Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 07: Global Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 08: Global Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 09: Global Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 10: Global Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 11: Global Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 12: Global Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 13: Global Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 14: Global Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 15: Global Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 16: Global Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 17: Global Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 18: Global Neuroprotection Therapeutics Market Share, by Region – 2022–2027
Fig 19: Global Neuroprotection Therapeutics Market Y-o-Y Growth Projections, by Region – 2022–2027
Fig 20: Global Neuroprotection Therapeutics Market Attractiveness Index, by Region – 2022–2027
Fig 21: North America Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 22: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: North America Vs North America Countries Vs North America Average
Fig 23: North America Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 24: North America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 25: North America Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 26: North America Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 27: North America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 28: North America Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 29: North America Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 30: North America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 31: North America Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 32: North America Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 33: North America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 34: North America Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 35: North America Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 36: North America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 37: North America Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 38: Europe Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 39: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: Europe Vs Europe Countries Vs Europe Average
Fig 40: Europe Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 41: Europe Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 42: Europe Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 43: Europe Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 44: Europe Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 45: Europe Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 46: Europe Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 47: Europe Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 48: Europe Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 49: Europe Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 50: Europe Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 51: Europe Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 52: Europe Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 53: Europe Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 54: Europe Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 55: East Asia Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 56: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 57: East Asia Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 58: East Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 59: East Asia Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 60: East Asia Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 61: East Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 62: East Asia Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 63: East Asia Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 64: East Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 65: East Asia Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 66: East Asia Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 67: East Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 68: East Asia Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 69: East Asia Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 70: East Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 71: East Asia Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 72: South Asia Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 73: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 74: South Asia Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 75: South Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 76: South Asia Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 77: South Asia Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 78: South Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 79: South Asia Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 80: South Asia Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 81: South Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 82: South Asia Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 83: South Asia Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 84: South Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 85: South Asia Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 86: South Asia Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 87: South Asia Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 88: South Asia Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 89: Latin America Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 90: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 91: Latin America Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 92: Latin America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 93: Latin America Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 94: Latin America Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 95: Latin America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 96: Latin America Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 97: Latin America Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 98: Latin America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 99: Latin America Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 100: Latin America Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 101: Latin America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 102: Latin America Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 103: Latin America Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 104: Latin America Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 105: Latin America Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 106: MEA Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 107: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: MEA Vs MEA Countries Vs MEA Average
Fig 108: MEA Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 109: MEA Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 110: MEA Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 111: MEA Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 112: MEA Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 113: MEA Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 114: MEA Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 115: MEA Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 116: MEA Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 117: MEA Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 118: MEA Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 119: MEA Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 120: MEA Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 121: MEA Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 122: MEA Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 123: Oceania Neuroprotection Therapeutics Market Value (US$ Thousand), Volume (Units) Forecast and Analysis, 2017–2027
Fig 124: Y-o-Y Growth Comparison of Neuroprotection Therapeutics Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 125: Oceania Neuroprotection Therapeutics Market Share, By Medical Condition – 2022–2027
Fig 126: Oceania Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Medical Condition – 2022–2027
Fig 127: Oceania Neuroprotection Therapeutics Market Attractiveness Index, By Medical Condition – 2022–2027
Fig 128: Oceania Neuroprotection Therapeutics Market Share, By Product – 2022–2027
Fig 129: Oceania Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Product – 2022–2027
Fig 130: Oceania Neuroprotection Therapeutics Market Attractiveness Index, By Product – 2022–2027
Fig 131: Oceania Neuroprotection Therapeutics Market Share, By Application – 2022–2027
Fig 132: Oceania Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Application – 2022–2027
Fig 133: Oceania Neuroprotection Therapeutics Market Attractiveness Index, By Application – 2022–2027
Fig 134: Oceania Neuroprotection Therapeutics Market Share, By End User – 2022–2027
Fig 135: Oceania Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By End User – 2022–2027
Fig 136: Oceania Neuroprotection Therapeutics Market Attractiveness Index, By End User – 2022–2027
Fig 137: Oceania Neuroprotection Therapeutics Market Share, By Country – 2022–2027
Fig 138: Oceania Neuroprotection Therapeutics Market Y-o-Y Growth Projections, By Country – 2022–2027
Fig 139: Oceania Neuroprotection Therapeutics Market Attractiveness Index, By Country – 2022–2027
Fig 140: United States Market share by Medical Condition, 2022
Fig 141: United States Market share by Product, 2022
Fig 142: United States Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 143: United States Market Share by End User, 2022
Fig 144: Canada Market share by Medical Condition, 2022
Fig 145: Canada Market share by Product, 2022
Fig 146: Canada Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 147: Canada Market Share by End User, 2022
Fig 148: Germany Market share by Medical Condition, 2022
Fig 149: Germany Market share by Product, 2022
Fig 150: Germany Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 151: Germany Market Share by End User, 2022
Fig 152: United Kingdom Market share by Medical Condition, 2022
Fig 153: United Kingdom Market share by Product, 2022
Fig 154: United Kingdom Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 155: United Kingdom Market Share by End User, 2022
Fig 156: France Market share by Medical Condition, 2022
Fig 157: France Market share by Product, 2022
Fig 158: France Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 159: France Market Share by End User, 2022
Fig 160: Russia Market share by Medical Condition, 2022
Fig 161: Russia Market share by Product, 2022
Fig 162: Russia Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 163: Russia Market Share by End User, 2022
Fig 164: Spain Market share by Medical Condition, 2022
Fig 165: Spain Market share by Product, 2022
Fig 166: Spain Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 167: Spain Market Share by End User, 2022
Fig 168: Italy Market share by Medical Condition, 2022
Fig 169: Italy Market share by Product, 2022
Fig 170: Italy Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 171: Italy Market Share by End User, 2022
Fig 172: China Market share by Medical Condition, 2022
Fig 173: China Market share by Product, 2022
Fig 174: China Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 175: China Market Share by End User, 2022
Fig 176: Japan Market share by Medical Condition, 2022
Fig 177: Japan Market share by Product, 2022
Fig 178: Japan Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 179: Japan Market Share by End User, 2022
Fig 180: South Korea Market share by Medical Condition, 2022
Fig 181: South Korea Market share by Product, 2022
Fig 182: South Korea Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 183: South Korea Market Share by End User, 2022
Fig 184: India Market share by Medical Condition, 2022
Fig 185: India Market share by Product, 2022
Fig 186: India Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 187: India Market Share by End User, 2022
Fig 188: Singapore Market share by Medical Condition, 2022
Fig 189: Singapore Market share by Product, 2022
Fig 190: Singapore Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 191: Singapore Market Share by End User, 2022
Fig 192: Indonesia Market share by Medical Condition, 2022
Fig 193: Indonesia Market share by Product, 2022
Fig 194: Indonesia Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 195: Indonesia Market Share by End User, 2022
Fig 196: Thailand Market share by Medical Condition, 2022
Fig 197: Thailand Market share by Product, 2022
Fig 198: Thailand Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 199: Thailand Market Share by End User, 2022
Fig 200: Brazil Market share by Medical Condition, 2022
Fig 201: Brazil Market share by Product, 2022
Fig 202: Brazil Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 203: Brazil Market Share by End User, 2022
Fig 204: Mexico Market share by Medical Condition, 2022
Fig 205: Mexico Market share by Product, 2022
Fig 206: Mexico Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 207: Mexico Market Share by End User, 2022
Fig 208: Turkey Market share by Medical Condition, 2022
Fig 209: Turkey Market share by Product, 2022
Fig 210: Turkey Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 211: Turkey Market Share by End User, 2022
Fig 212: GCC Countries Market share by Medical Condition, 2022
Fig 213: GCC Countries Market share by Product, 2022
Fig 214: GCC Countries Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 215: GCC Countries Market Share by End User, 2022
Fig 216: South Africa Market share by Medical Condition, 2022
Fig 217: South Africa Market share by Product, 2022
Fig 218: South Africa Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 219: South Africa Market Share by End User, 2022
Fig 220: Australia Market share by Medical Condition, 2022
Fig 221: Australia Market share by Product, 2022
Fig 222: Australia Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 223: Australia Market Share by End User, 2022
Fig 224: New Zealand Market share by Medical Condition, 2022
Fig 225: New Zealand Market share by Product, 2022
Fig 226: New Zealand Neuroprotection Therapeutics Market Value (US$ Mn) and Forecast 2022–2027
Fig 227: New Zealand Market Share by End User, 2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What valuation does the neuroprotection therapeutics market enjoy?
The global neuroprotection therapeutics market stands at US$ 61.25 billion.
At what CAGR is the market expected to rise?
Demand for neuroprotection therapeutics is anticipated to increase at 6.8% CAGR through 2027.
What will the value of the neuroprotection therapeutics market be by 2027?
The market for neuroprotection therapeutics is set to reach US$ 85.1 billion by 2027.
Which are the key companies providing neuroprotection therapeutic solutions?
Allergan PLC, AstraZeneca PLC, and Astrocyte Pharmaceuticals Inc. are key companies in the market.
At what pace is the China neuroprotection therapeutics market expected to evolve?
The neuroprotection therapeutics market in China is set to rise at 6.5% CAGR.
Which neuroprotection therapeutics product holds the highest market share?
Free radical trapping agents account for 38% share of the global market.
Neuroprotection Therapeutics Market